MyoKardia, Inc. (NASDAQ:MYOK) Rating Increased to Hold at ValuEngine
MyoKardia, Inc. (NASDAQ:MYOK) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Monday.
Several other brokerages have also commented on MYOK. Zacks Investment Research lowered MyoKardia from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. TheStreet raised MyoKardia from a “d+” rating to a “c” rating in a research note on Thursday, July 6th. BidaskClub raised MyoKardia from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Wells Fargo & Company reissued an “outperform” rating and set a $48.00 price target (up previously from $31.00) on shares of MyoKardia in a research note on Monday. Finally, BMO Capital Markets reissued an “outperform” rating and set a $32.00 price target on shares of MyoKardia in a research note on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $35.00.
Shares of MyoKardia (NASDAQ MYOK) traded up 83.38% during trading on Monday, hitting $31.45. The company’s stock had a trading volume of 8,757,035 shares. The stock’s market cap is $989.26 million. MyoKardia has a one year low of $10.55 and a one year high of $32.30. The company has a 50-day moving average price of $14.02 and a 200-day moving average price of $13.13.
MyoKardia (NASDAQ:MYOK) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.04. The firm had revenue of $5.60 million for the quarter, compared to analysts’ expectations of $6.73 million. MyoKardia had a negative return on equity of 15.27% and a negative net margin of 39.44%. MyoKardia’s revenue was up 60.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) EPS. Equities analysts predict that MyoKardia will post ($1.54) EPS for the current fiscal year.
In related news, CEO Anastasios Gianakakos sold 4,300 shares of MyoKardia stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $16.62, for a total transaction of $71,466.00. Following the completion of the transaction, the chief executive officer now directly owns 512,463 shares in the company, valued at approximately $8,517,135.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 46.10% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp increased its position in shares of MyoKardia by 24.1% in the fourth quarter. State Street Corp now owns 178,189 shares of the biotechnology company’s stock valued at $2,307,000 after buying an additional 34,609 shares in the last quarter. Norges Bank bought a new position in shares of MyoKardia during the fourth quarter valued at about $869,000. Teachers Advisors LLC increased its position in shares of MyoKardia by 42.1% in the fourth quarter. Teachers Advisors LLC now owns 28,145 shares of the biotechnology company’s stock valued at $364,000 after buying an additional 8,342 shares in the last quarter. Daiwa SB Investments Ltd. bought a new position in shares of MyoKardia during the first quarter valued at about $170,000. Finally, Hamilton Lane Advisors LLC increased its position in shares of MyoKardia by 70.6% in the first quarter. Hamilton Lane Advisors LLC now owns 37,287 shares of the biotechnology company’s stock valued at $490,000 after buying an additional 15,433 shares in the last quarter. Hedge funds and other institutional investors own 47.74% of the company’s stock.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.